List of the 3 largest pharmaceutical companies in the Lake Geneva region

Switzerland is world famous for its pharmaceutical industry. There are many different pharmaceutical companies all over Switzerland. Below we present 3 from the Lake Geneva region. All 3 are part of our list of the 100 largest pharmaceutical companies in Switzerland.

1. Ferring International Centre SA, Saint-Prex: approx. 1.5 billion CHF sales (no current turnover available)

Ferring was founded in 1950 as a laboratory in Malmö, Sweden. In 1954, the company changed its name to Ferring. Since 2006, the headquarters of the Ferring Group have been located in Saint-Prex on Lake Geneva. The pharmaceutical company is focused on the research and development of peptide-based drugs. Ferring products are used in the fields of endocrinology, fertility, gastroenterology, obstetrics and urology. The group of companies is active worldwide with numerous subsidiaries. Development sites are located in Basel (Switzerland), Be’er Tuvia (Israel), Glasgow (UK), Copenhagen (Denmark), Mumbai (India) and Parsippany (USA), among others. The group employs about 5,000 people. The owner is the son of Ferring founder Frederik Paulsen.

2. OM Pharma Ltd., Meyrin: CHF 150 million in turnover

Until 2020, OM Pharma belonged to the Swiss pharmaceutical group Vifor Pharma. At that time, the latter sold its subsidiary for CHF 435 million to the investment company Optimus Holding. OM Pharma was founded as early as 1937 and was family-owned until 2009, when it was acquired by Vifor Pharma. The business model is the development, manufacture and distribution of drugs for acute or chronic immunological diseases associated with infections and inflammations. Another focus is on drugs for vascular diseases. The company employs around 450 people and is represented in over 100 countries worldwide.

3 Debiopharm International SA, Lausanne: no sales data available (estimated > CHF 40 million)

Debiopharm was founded in 1979 by Rolland-Yves Mauvernay and is family-owned following his death in 2017. The company is focused on the development and manufacture of biopharmaceutical drugs. Debiopharm is a global leader in injectable sustained-release technologies based on polylactic-co-glycolic acid (PLGA). The business comprises three divisions: drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing) and digital health investment (Debiopharm Innovation Fund). The Debiopharm Group employs 420 people.

Picture Source: Unsplash ( Michal Dolnik, 14.12.21)

You might also have interest in these lists: